Research ArticleClinical Studies

Plasma Concentration of the Lipid Peroxidation (LP) Biomarker 4-Ηydroxynonenal (4-HNE) in Benign and Cancer Patients

MAARET ESKELINEN, IINA SAIMANEN, RIIKA KOSKELA, ANU HOLOPAINEN, TUOMAS SELANDER and MATTI ESKELINEN
In Vivo March 2022, 36 (2) 773-779; DOI: https://doi.org/10.21873/invivo.12764

Abstract

Background/Aim: The present study investigated the plasma concentration of the lipid peroxidation (LP) biomarker 4-hydroxynonenal (4-HNE) in benign and cancer patients having the rectus sheath block (RSB) analgesia after midline laparotomy. Plasma concentrations of catalase (CAT) and malondialdehyde (MDA) were used as a reference. Patients and Methods: This study assessed three LP biomarkers; CAT, MDA and 4-HNE and compared the plasma levels to the patient satisfaction 24 h postoperatively (SFS24; 0=fully unsatisfied; 10=fully satisfied); the overall pain at rest (NRSr) and when pressing the wound at 20 Newton force (NRSp) were surveyed and filed on a 11-point numeric rating scale at 24 h following surgery (NRS; 0=no pain; 10=worst pain). There were 56 patients in the study, of whom 12 were excluded due to missing plasma samples. The final study cohort consisted of 15 patients with benign disease and 29 patients with cancer. Results: The RSB analgesia enhanced significantly the SFS24 scores in the study groups (p=0.001). The plasma 4-HNE decreased immediately after operation (POP1) and the postoperative decrease between the preoperative and the POP1 values in the 4-HNE marker were statistically significant (p<0.001). The individual plasma 4-HNE and MDA concentration correlated significantly in benign and cancer patients (r=0.413, p<0.001). Conclusion: The present study confirms the applicability of the plasma biomarker 4-HNE to cast further light on the postoperative pain in midline laparotomy patients.

Failure in antioxidant defenses could lead to formation of reactive oxidative species (ROS) and lipid peroxidation (LP) (1-9). The uncontrolled ROS is called oxidative stress (OS) and is a common feature in cancer cells (1). OS in cancer cells could be demonstrated by an increase in OS markers and ROS in cancer cells can be counteracted by substances known as antioxidants: vitamin E and C, flavonoids and carotenoids (10, 11). The most important antioxidative enzymes are catalase (CAT) (12, 13), glutathione peroxidase (GPX1) (4, 14) and superoxide dismutase (SOD1) (15, 16). The role of LP in etiology of cancer, neurodegenerative and cardiovascular diseases, has motivated researchers to clarify the mechanism of LP and to develop biomarkers (7, 17-19). LP proceeds by three mechanisms; (i) free radical oxidation, (ii) free radical independent non-enzymatic oxidation, and (iii) enzymatic oxidation (1, 2). Polyunsaturated fatty acids (PUFAs) and cholesterol are oxidized through enzymatic and non-enzymatic routes. Malondialdehyde (MDA) and 4-Hydroxynonenal (4-HNE) are the ROS that cause OS in cells, targeting the subcellular structures to form covalent protein adducts (1, 2). 4-HNE is an α,β-unsaturated hydroxyalkenal that is produced by LP in cells. 4-HNE has 3 reactive groups: an aldehyde, a double-bond at carbon 2, and a hydroxy group at carbon 4 (1, 2).

As far as we know, the differences in the LP stress biomarker 4-HNE plasma concentrations in midline laparotomy in patients with benign disease versus cancer is unknown. Therefore, the present study investigated the 4-HNE plasma concentrations in patients with benign disease versus cancer following midline laparotomy. Our aim was to determine plasma 4-HNE levels in patients with benign disease versus patients with cancer and to determine the association between plasma 4-HNE concentrations and the patient satisfaction 24 h following surgery (SFS24), as well as the overall pain at rest (NRSr) and at 2 kg pressing (NRSp).

Patients and Methods

Patients in the study. The study was approved by the Ethics Committee of the Northern Savo Hospital District, Kuopio, Finland (DNRO 120/2011, November 11, 2011) and was registered in the EudraCT database (EudraCT number 2011-005136-25, Consort diagram, Figure 1) and in the ClinicalTrials.gov database (ClinicalTrials.gov Identifier: NCT02869841). The study protocol and inclusion/exclusion criteria of the study patients were detailed in the previous report by Purdy et al. (3).

Figure 1.
Figure 1.

Study flowchart.

Plasma biomarkers and outcome measures. The primary outcome measures were the plasma concentrations of CAT, MDA and 4-HNE biomarkers measured at three time points with high-sensitivity assays: before (PRE), immediately after (POP1) and 24 h postoperatively (POP2) in the control group versus three active groups. The patient satisfaction at 24 h postoperatively were filed on a 11-point numeric rating scale (SFS24; 0=fully unsatisfied; 10=fully satisfied) and the overall pain at rest (NRSr) and at 2 kg pressing (NRSp) was surveyed and filed on a 11-point numeric rating scale 24 h following surgery (NRS; 0=no pain; 10=worst pain).

Samples collection. EDTA-blood samples were taken at the pre-specified time-points and centrifuged at 1,000 × g for 15 min. Plasma was separated and stored frozen at –70°C until further analysis. The plasma CAT assays were performed using enzyme-linked immunosorbent assay ELISA Kit (Cloud-Clone Corporation, Katy, TX, USA). Plasma MDA concentrations were determined by the MDA ELISA Kit (E-EL-0060, Elabscience, Houston, TX, USA). The manufacturer’s intra-assay and inter-assay Cvs were 5.6% and 6.28%, respectively. The plasma 4-hydroxynonenal (4-HNE) concentrations were measured at three time points with 4-Hydroxynonenal Elisa kit (Cat# 9705, Alpha Diagnostic Intl., San Antonio, TX, USA): before (PRE), immediately after (POP1) and 24 h postoperatively (POP2). The manufacturer’s intra- and inter-assay Cvs were <8% and <10%.

Statistical analysis. Data are presented as means and standard deviations or frequencies and percentages, where appropriate. Differences in baseline characteristics between groups were tested by Fisher’s exact test and in the case of continuous data, the analysis was performed by Kruskal-Wallis test. Group differences at three time points were tested by the Wilcoxon signed rank test and the Kruskal-Wallis test. The plasma CAT, MDA and 4-HNE concentrations and differences in the patients with benign diseases and cancer were tested by the Mann-Whitney U-test. Linear mixed effect (LME) model was used to test time effect. In LME analysis plasma concentrations were log transformed. The results of the laboratory measurements are presented as median concentrations with interquartile range as distributions were right-skewed. p-Values under 0.05 were considered statistically significant. The Spearman’s method was used to test for correlation for plasma 4-HNE concentrations versus MDA concentrations. Data were analyzed by IBM SPSS statistical software (SPSS Statistics 26.0.0.1; IBM, Armonk, NY, USA).

Results

Patient data. There were 56 patients, of whom 12 were excluded due to missing plasma samples. The final study cohort consisted of 15 patients with benign disease and 29 patients with cancer (Table I). There were significantly less benign patients than cancer patients in the control group (one benign patient versus seven cancer patients, benign-cancer ratio=14.3%) than that in the RSB study groups combined (14 benign patients versus 22 cancer patients, benign-cancer ratio=63.6%). The RSB analgesia enhanced significantly the median SFS24 scores in the following order: control, single dose, repeated dose and continuous dose group (8, 9, 9.5 and 10, respectively; p=0.001, Table I). There were no statistically significant differences detected in the NRSr and NRSp scores between the four study groups (NRSr p=0.41 and NRSp p=0.42, Table I).

View this table:
Table I.

The clinical data of the four study groups. Data are mean (±standard deviation) or number of cases.

Plasma CAT, MDA and 4-HNE concentrations in the RSB study groups. There were no differences detected in the CAT, MDA and 4-HNE concentrations between the four study groups preoperatively and following surgery (Table II). Although, the patients in the control group had a trend for a slightly higher median CAT levels preoperatively compared to the single dose group, repeated dose and continuous dose groups (0.95 pg/ml versus 0.74, 0.61 and 0.61 pg/ml, respectively, Table II). The patients in the control group had a trend for lower median MDA concentrations preoperatively and following surgery (POP1), compared to RSB study groups (control group, 642/541 ng/ml versus single dose; 872/753 ng/ml and repeated dose; 795/555 ng/ml and continuous infusion; 983/638 ng/ml, Table II). There were no significant differences detected in the preoperative 4-HNE concentrations in RSB study groups and between control groups (Table II). However, the patients in the control group and in the RSB study groups had a trend for lower 4-HNE concentrations following surgery and the most significant postoperative decrease was in patients in the repeated dose and continuous dose groups (Table II).

View this table:
Table II.

The plasma catalase (CAT), malonidialdehyde (MDA) and 4-hydroxynonenal (4-HNE) concentrations in the four study groups. Plasma concentrations were measured before (PRE), immediately after (POP1) and 24 h after (POP2) surgery. Median (interquartile range) concentrations are shown. The Kruskall-Wallis test was used.

The alteration of plasma CAT, MDA and 4-HNE levels following surgery. The alteration of plasma CAT, MDA and 4-HNE marker levels in the study groups combined are shown in Table III. There were statistically significant increases in the median plasma concentrations of CAT preoperatively (PRE) and immediately after operation (POP1) (52.5% increase, p<0.001, Table III). Then the median plasma concentrations of CAT marker decreased 24 h postoperatively (POP2) (p=0.001, Table III). The median plasma concentrations of MDA decreased 24 h postoperatively (POP2) and the decrease was significant (31.6% decrease, p<0.001, Table III). There was significant decrease in the median plasma concentrations of MDA preoperatively and immediately after operation (p<0.001, Table III). Also, the median plasma concentrations of 4-HNE decreased 24 h following surgery (POP2) and the decrease was statistically significant (50.2% decrease, p<0.001, Table III).

View this table:
Table III.

The alteration of the plasma catalase (CAT), malonidialdehyde (MDA) and 4-hydroxynonenal (4-HNE) concentrations following surgery in all groups combined (all patients). Plasma concentrations were measured before (PRE), immediately after (POP1) and 24 h postoperatively (POP2). Median (interquartile range) concentrations are shown

Plasma CAT, MDA and 4-HNE concentrations in benign versus cancer patients. The median (interquartile range) plasma concentrations of CAT, MDA and 4-HNE did not differ significantly between the benign and cancer patients preoperatively (Table IV). Patients in the cancer group had a trend for higher median CAT levels postoperatively (POP1) compared to benign patients (Table IV). There was a statistically significant difference in the median MDA concentrations between benign and cancer patients immediately following surgery (POP1), with the cancer patients showing significantly lower MDA concentrations postoperatively (p=0.021, Table IV). There was a statistically significant decrease in 4-HNE concentrations postoperatively in benign and cancer patients (Figure 2 and Table IV). In addition, the time effect in the linear mixed model in plasma 4-HNE was statistically significant (Table IV).

View this table:
Table IV.

The plasma catalase (CAT), malonidialdehyde (MDA) and 4-hydroxynonenal (4-HNE) concentrations in the patients with benign diseases (n=15) and in those with cancer (n=29). Plasma concentrations were measured before (PRE), immediately after (POP1) and 24 h postoperatively (POP2). Median (interquartile range) concentrations are shown. Mann-Whitney U-test was used.

Figure 2.
Figure 2.

Plasma median 4-hydroxynonenal (4-HNE) concentrations in benign and cancer patients preoperatively, immediately after operation and 24 h after operation. p≤0.001 using the Wilcoxon signed-rank test.

Correlation of SFS24, NRSr and NRSp versus the LP biomarkers MDA and 4-HNE. NRSr correlated significantly to 4-HNE plasma concentrations (p=0.026). However, there was no significant correlation between SFS24 or NRSp versus MDA or 4-HNE plasma concentrations. The median (interquartile range) plasma concentrations of MDA correlates significantly to 4-HNE concentrations in benign and cancer patients (Figure 3, r=0.347, p<0.001).

Figure 3.
Figure 3.

Plasma malonidialdehyde (MDA) concentrations versus plasma 4-hydroxynonenal (4-HNE) concentrations in benign and cancer patients shown as Jitterplot. Spearman’s r=0.413, p<0.001).

Discussion

Albeit the surgical procedure is a common cause of LP in patients with midline laparotomy, the assessment of LP stress biomarker 4-HNE concentrations is rarely reported (1). Especially, the 4-HNE plasma levels versus the patient satisfaction and the NRS pain scores following surgery in midline laparotomy patients is unknown. To cast further light on this issue, the present study was designed to conduct a detailed analysis of the i) Plasma CAT, MDA and 4-HNE concentrations in benign versus cancer patients, ii) The alteration of plasma CAT, MDA and 4-HNE levels in RSB study groups, and iii) Plasma CAT, MDA and 4-HNE concentrations in RSB study groups, to establish whether these plasma biomarkers could improve the detection of OS or LP stress following surgery. The original study hypothesis was that RSB analgesia could lower the pain and enhance satisfaction in midline laparotomy patients. Therefore, the main aim of the study was to assess the relation between plasma 4-HNE concentrations and RSB analgesia in patients with midline laparotomy.

The primary products of LP are lipid hydroperoxides (LOOH) (1, 2). Among the many different aldehydes which can be formed as secondary products during LP, MDA and 4-HNE are receiving most attention because they are being considered as possible risk factor of cancer, cardiovascular diseases, chronic inflammation, diabetes, liver disease, Parkinson’s disease, and respiratory distress syndrome (1, 2). In addition, LP products have been suggested as a possible risk factor for Alzheimer’s disease (1, 2). In everyday life, attention must be paid to household oils used regularly in caterings and cooking, because in those processes very high amounts of LP products are generated and they can be easily absorbed through the diet (1, 2). The production and plasma level of MDA and 4-HNE can be measured and used as a biomarker to estimate the degree of oxidative stress and lipid peroxidation in human disease (1, 2). Both are toxic substances reacting with deoxyadenosine in DNA and forming DNA adducts, which are mutagenic (1, 2). The aldehydes which can be formed as secondary products during LP have been reviewed by Ayala et al. (2), where MDA is shown to be the most mutagenic product of LP, whereas 4-HNE is the most toxic product (2).

One possible bias of the study is that the patients in the control group and in the single-dose group had significantly higher mean body weight and body mass index than patients in the repeated-dose and continuous-infusion group. Unfortunately, we have no explanation for this trend, and due to the small sample size (n=44), its significance should be very carefully interpreted. Despite that, following surgery, the RSB study groups did not differ in terms of NRS pain at rest and pain under 2 kg pressure to the wound area. However, the statistically significant inverse correlation between the individual plasma 4-HNE values and NRS pain at rest scores might suggest some role for 4-HNE. In addition, SFS24 differed significantly between study groups, the repeated-dose (score 9.5) and continuous-infusion group (score 10) patients having highest SFS24 scores 24 h following surgery.

Although, the NRSr correlated significantly to 4-HNE plasma concentrations (p=0.026), there was no statistically significant difference shown between plasma 4-HNE concentrations and the NRSr/NRSp and SFS24 scores in the control and three RSB study groups. Interestingly, in the present study there was a significant decrease in 4-HNE concentrations following surgery in benign and cancer patients. In addition, the time effect in the linear mixed model in plasma 4-HNE was statistically significant. Saimanen et al. (12, 13) reported earlier that RSB-analgesia significantly increases the CAT concentrations and decreases the NT concentrations (20) immediately after operation. Surprisingly CAT concentrations dropped back 24 h postoperatively. Kärkkäinen et al. (15) reported earlier that RSB-analgesia does significantly increase the SOD-1 concentrations immediately after operation, but SOD-1 concentration drops back 24 h postoperatively. Martins et al. (21) have previously demonstrated that accumulation of 4-HNE plays a major role in the establishment and progression of pain showing that the 4-HNE is an endogenous aldehyde generated during oxidative stress, mainly through the LP process in the mitochondria. Therefore, increased 4-HNE adducts in the injured tissue positively correlates with pain (21). Sauer et al. (22) showed that the Delphinidin (DEL), a plant-derived antioxidant with potential to treat inflammatory pain, prevented 4-HNE-induced mechanical hyperalgesia, cold allodynia, and an increase in the intracellular calcium concentration into transient receptor potential ankyrin 1 expressing cells. The aim of their study was to develop a well-tolerated cyclodextrin (CD)-DEL complex with enhanced bioavailability and to investigate the mechanisms behind its antinociceptive effects in a preclinical model of inflammatory pain, and formation of the LP product 4-HNE.

Conclusion

The enhanced ROS production alters the mitochondrial genome and proteome function through the accumulation of LP products, such as 4-HNE and MDA. Some mitochondrial protein products (e.g., Sirtuin3, SIRT3) can reduce ROS levels by modulating key antioxidant enzymes, such as manganese superoxide dismutase (MnSOD) (23). The present study showed that plasma 4-HNE concentrations decreased significantly after operation in all patients and 4-HNE concentrations were inversely correlated to the overall pain at rest (the NRSr pain scores). The present study confirms the applicability of the plasma biomarker 4-HNE to cast further light on the postoperative pain in midline laparotomy patients.

Acknowledgements

The study was funded by the Heikki, Aino and Aarne Korhonen Foundation, Kuopio, Finland, and the Päivikki and Sakari Sohlberg Foundation, Helsinki, Finland.

Footnotes

  • ↵* These Authors contributed equally to this study.

  • Authors’ Contributions

    The Authors M.E., I.S., R.K, A.H., T.S. and M.E. did the collection and analysis of data. M.E., I.S., R.K, A.H., T.S. and M.E. drafted and revised the manuscript, read and approved the final article.

  • Conflicts of Interest

    The Authors report no conflicts of interest or have any financial ties to disclose.

  • Received January 21, 2022.
  • Revision received February 8, 2022.
  • Accepted February 15, 2022.

References

  1. ↵
    1. Bartsch H and
    2. Nair J
    : Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 391(5): 499-510, 2006. PMID: 16909291. DOI: 10.1007/s00423-006-0073-1
    OpenUrlCrossRefPubMed
  2. ↵
    1. Ayala A,
    2. Muñoz MF and
    3. Argüelles S
    : Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014: 360438, 2014. PMID: 24999379. DOI: 10.1155/2014/360438
    OpenUrlCrossRefPubMed
  3. ↵
    1. Purdy M,
    2. Kokki M,
    3. Anttila M,
    4. Aspinen S,
    5. Juvonen P,
    6. Selander T,
    7. Kokki H,
    8. Pulkki K and
    9. Eskelinen M
    : Does post-surgery placement of rectus sheath block analgesia alter the oxidative stress biomarker 8-OHdG concentrations: a randomised trial of patients with cancer and benign disease. Cancer Genomics Proteomics 13(3): 239-244, 2016. PMID: 27107066.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Purdy M,
    2. Kärkkäinen J,
    3. Kokki M,
    4. Anttila M,
    5. Aspinen S,
    6. Juvonen P,
    7. Kokki H,
    8. Pulkki K,
    9. Rantanen T and
    10. Eskelinen M
    : Does rectus sheath block analgesia alter levels of the oxidative stress biomarker glutathione peroxidase: a randomised trial of patients with cancer and benign disease. Anticancer Res 37(2): 897-902, 2017. PMID: 28179349. DOI: 10.21873/anticanres.11396
    OpenUrlAbstract/FREE Full Text
    1. Bakirezer SD,
    2. Yaltirik CK,
    3. Kaya AH,
    4. Yilmaz SG,
    5. Ozdogan S,
    6. Billur D and
    7. Isbir T
    : The evaluation of glutathione reductase and malondialdehyde levels in patients with lumbar disc degeneration disease. In Vivo 33(3): 811-814, 2019. PMID: 31028201. DOI: 10.21873/invivo.11543
    OpenUrlAbstract/FREE Full Text
    1. Dogaru G,
    2. Bulboaca A,
    3. Boarescu PM,
    4. Ciumarnean L,
    5. Rus V,
    6. Sitar-Taut AV,
    7. Munteanu C,
    8. Bodisz G and
    9. Stanescu I
    : The effect of mofettes on oxidative stress/antioxidant balance in experimental myocardial ischemia. In Vivo 33(6): 1911-1920, 2019. PMID: 31662519. DOI: 10.21873/invivo.11685
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Tsounapi P,
    2. Honda M,
    3. Hikita K,
    4. Sofikitis N and
    5. Takenaka A
    : Oxidative stress alterations in the bladder of a short-period type 2 diabetes rat model: antioxidant treatment can be beneficial for the bladder. In Vivo 33(6): 1819-1826, 2019. PMID: 31662508. DOI: 10.21873/invivo.11674
    OpenUrlAbstract/FREE Full Text
    1. Sardaro N,
    2. Della Vella F,
    3. Incalza MA,
    4. DI Stasio D,
    5. Lucchese A,
    6. Contaldo M,
    7. Laudadio C and
    8. Petruzzi M
    : Oxidative stress and oral mucosal diseases: an overview. In Vivo 33(2): 289-296, 2019. PMID: 30804105. DOI: 10.21873/invivo.11474
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. VON Woedtke T,
    2. Schmidt A,
    3. Bekeschus S,
    4. Wende K and
    5. Weltmann KD
    : Plasma medicine: a field of applied redox biology. In Vivo 33(4): 1011-1026, 2019. PMID: 31280189. DOI: 10.21873/invivo.11570
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Carini F,
    2. Mazzola M,
    3. Rappa F,
    4. Jurjus A,
    5. Geagea AG,
    6. Al Kattar S,
    7. Bou-Assi T,
    8. Jurjus R,
    9. Damiani P,
    10. Leone A and
    11. Tomasello G
    : Colorectal carcinogenesis: role of oxidative stress and antioxidants. Anticancer Res 37(9): 4759-4766, 2017. PMID: 28870894. DOI: 10.21873/anticanres.11882
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Mokbel K and
    2. Mokbel K
    : Chemoprevention of breast cancer with vitamins and micronutrients: a concise review. In Vivo 33(4): 983-997, 2019. PMID: 31280187. DOI: 10.21873/invivo.11568
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Saimanen I,
    2. Kuosmanen V,
    3. Kärkkäinen J,
    4. Selander T,
    5. Aspinen S,
    6. Holopainen A,
    7. Rantanen T and
    8. Eskelinen M
    : Cholecystectomy patients with high plasma level of catalase have significantly lower analgesia requirement: a prospective study of two different cholecystectomy techniques with special reference to patients with cancer. Anticancer Res 38(9): 5417-5422, 2018. PMID: 30194197. DOI: 10.21873/anticanres.12872
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Saimanen I,
    2. Kärkkäinen J,
    3. Selander T,
    4. Purdy M,
    5. Kokki M,
    6. Kokki H and
    7. Eskelinen M
    : Plasma catalase in relation to pain following midline laparotomy: a prospective study of patients with benign diseases and patients with cancer. Anticancer Res 38(11): 6479-6484, 2018. PMID: 30396975. DOI: 10.21873/anticanres.13011
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Kärkkäinen J,
    2. Aspinen S,
    3. Harju J,
    4. Juvonen P,
    5. Pulkki K and
    6. Eskelinen M
    : Plasma glutathione peroxidase (GPX1) levels and oxidative stress in gallstone patients operated with two different cholecystectomy techniques: a randomized study with special reference to cancer patients. Anticancer Res 37(12): 6921-6927, 2017. PMID: 29187474. DOI: 10.21873/anticanres.12156
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Kärkkäinen J,
    2. Selander T,
    3. Purdy M,
    4. Juvonen P and
    5. Eskelinen M
    : Patients with increased levels of the oxidative stress biomarker SOD1 appear to have diminished postoperative pain after midline laparotomy: a randomised trial with special reference to postoperative pain score (NRS). Anticancer Res 38(2): 1003-1008, 2018. PMID: 29374733. DOI: 10.21873/anticanres.12315
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Kärkkäinen J,
    2. Saimanen I,
    3. Selander T,
    4. Aspinen S,
    5. Harju J,
    6. Juvonen P and
    7. Eskelinen M
    : Gallstone patients with enhanced oxidative stress biomarker superoxide dismutase (SOD1) plasma levels have significantly lower number of postoperative analgesic oxycodone doses: a prospective study with special reference to cancer patients. Anticancer Res 38(6): 3573-3578, 2018. PMID: 29848712. DOI: 10.21873/anticanres.12630
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Luongo M,
    2. Brigida AL,
    3. Mascolo L and
    4. Gaudino G
    : Possible therapeutic effects of ozone mixture on hypoxia in tumor development. Anticancer Res 37(2): 425-435, 2017. PMID: 28179287. DOI: 10.21873/anticanres.11334
    OpenUrlAbstract/FREE Full Text
    1. Wakana H,
    2. Kono H,
    3. Fukushima H,
    4. Nakata Y,
    5. Akazawa Y,
    6. Maruyama S,
    7. Hagio K,
    8. Fujii H and
    9. Ichikawa D
    : Effects of medium-chain triglycerides administration in chemically-induced carcinogenesis in mice. Anticancer Res 39(12): 6653-6660, 2019. PMID: 31810930. DOI: 10.21873/anticanres.13880
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. DE Angelis PM,
    2. Dorg L,
    3. Pham S and
    4. Andersen SN
    : DNA repair protein expression and oxidative/nitrosative stress in ulcerative colitis and sporadic colorectal cancer. Anticancer Res 41(7): 3261-3270, 2021. PMID: 34230120. DOI: 10.21873/anticanres.15112
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Kuosmanen V,
    2. Saimanen I,
    3. Rahkola D,
    4. Kärkkäinen J,
    5. Selander T,
    6. Purdy M,
    7. Kokki H,
    8. Kokki M and
    9. Eskelinen M
    : Rectus sheath block (RSB) analgesia could enhance significantly the patient satisfaction following midline laparotomy in benign disease and in cancer: a prospective study with special reference to nitrosative stress marker nitrotyrosine (NT) plasma concentrations. Anticancer Res 39(3): 1383-1389, 2019. PMID: 30842172. DOI: 10.21873/anticanres.13252
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Martins BB,
    2. Hösch NG,
    3. Alcantara QA,
    4. Budas GR,
    5. Chen CH,
    6. Mochly-Rosen D,
    7. Ferreira JCB and
    8. Zambelli VO
    : Activation of PKCε-ALDH2 axis prevents 4-HNE-induced pain in mice. Biomolecules 11(12): 1798, 2021. PMID: 34944441. DOI: 10.3390/biom11121798
    OpenUrlCrossRefPubMed
  22. ↵
    1. Sauer RS,
    2. Krummenacher I,
    3. Bankoglu EE,
    4. Yang S,
    5. Oehler B,
    6. Schöppler F,
    7. Mohammadi M,
    8. Güntzel P,
    9. Ben-Kraiem A,
    10. Holzgrabe U,
    11. Stopper H,
    12. Broscheit JA,
    13. Braunschweig H,
    14. Roewer N,
    15. Brack A and
    16. Rittner HL
    : Stabilization of delphinidin in complex with sulfobutylether-β-cyclodextrin allows for antinociception in inflammatory pain. Antioxid Redox Signal 34(16): 1260-1279, 2021. PMID: 32977733. DOI: 10.1089/ars.2019.7957
    OpenUrlCrossRefPubMed
  23. ↵
    1. Ilari S,
    2. Giancotti LA,
    3. Lauro F,
    4. Gliozzi M,
    5. Malafoglia V,
    6. Palma E,
    7. Tafani M,
    8. Russo MA,
    9. Tomino C,
    10. Fini M,
    11. Salvemini D,
    12. Mollace V and
    13. Muscoli C
    : Natural antioxidant control of neuropathic pain-exploring the role of mitochondrial SIRT3 pathway. Antioxidants (Basel) 9(11): 1103, 2020. PMID: 33182469. DOI: 10.3390/antiox9111103
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Plasma Concentration of the Lipid Peroxidation (LP) Biomarker 4-Ηydroxynonenal (4-HNE) in Benign and Cancer Patients
MAARET ESKELINEN, IINA SAIMANEN, RIIKA KOSKELA, ANU HOLOPAINEN, TUOMAS SELANDER, MATTI ESKELINEN
In Vivo Mar 2022, 36 (2) 773-779; DOI: 10.21873/invivo.12764
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Keywords